Have a feature idea you'd love to see implemented?
Let us know!
QTTB Q32 Bio Inc.
Price (delayed)
$27.04
Market cap
$329.37M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$6.71
Enterprise value
$258.04M
homology medicines is a genetic medicines company translating proprietary gene editing and gene therapy technologies into novel treatments for patients with rare diseases.
Highlights
QTTB's EPS has soared by 92% YoY and by 85% from the previous quarter
QTTB's quick ratio has surged by 53% year-on-year
QTTB's net income is up by 19% year-on-year but it is down by 8% since the previous quarter
Q32 Bio's revenue has plunged by 100% from the previous quarter and by 100% YoY
Q32 Bio's gross profit has shrunk by 100% QoQ and by 100% YoY
Key stats
What are the main financial stats of QTTB
Market
Valuations
Earnings
Shares outstanding
12.18M
Market cap
$329.37M
Enterprise value
$258.04M
Price to earnings (P/E)
N/A
Price to book (P/B)
17.82
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$49.66M
EBITDA
-$47.89M
Free cash flow
-$77.72M
Per share
Balance sheet
Liquidity
EPS
-$6.71
Free cash flow per share
-$6.44
Book value per share
$1.52
Revenue per share
$0
TBVPS
$8.66
Total assets
$104.54M
Total liabilities
$86.25M
Debt
$18.4M
Equity
$18.3M
Working capital
$79.52M
Debt to equity
1.01
Current ratio
6.53
Quick ratio
6.24
Net debt/EBITDA
1.49
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-46.4%
Return on equity
N/A
Return on invested capital
-165.8%
Return on capital employed
-55.1%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
QTTB stock price
How has the Q32 Bio stock price performed over time
Intraday
-0.88%
1 week
-24.11%
1 month
-44.94%
1 year
168.25%
YTD
147.17%
QTD
-39.4%
Financial performance
How have Q32 Bio's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$63.68M
Net income
-$49.66M
Gross margin
N/A
Net margin
N/A
Q32 Bio's revenue has plunged by 100% from the previous quarter and by 100% YoY
Q32 Bio's gross profit has shrunk by 100% QoQ and by 100% YoY
The operating income has declined by 21% since the previous quarter and by 12% year-on-year
QTTB's net income is up by 19% year-on-year but it is down by 8% since the previous quarter
Growth
What is Q32 Bio's growth rate over time
Valuation
What is Q32 Bio stock price valuation
P/E
N/A
P/B
17.82
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
QTTB's EPS has soared by 92% YoY and by 85% from the previous quarter
QTTB's equity has dropped by 79% year-on-year and by 45% since the previous quarter
Q32 Bio's revenue has plunged by 100% from the previous quarter and by 100% YoY
Efficiency
How efficient is Q32 Bio business performance
Q32 Bio's return on invested capital has shrunk by 94% QoQ
The ROA has contracted by 40% YoY and by 17% from the previous quarter
Dividends
What is QTTB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for QTTB.
Financial health
How did Q32 Bio financials performed over time
The total assets is 21% greater than the total liabilities
The total liabilities has soared by 66% YoY but it has contracted by 4.9% from the previous quarter
The current ratio has surged by 55% year-on-year
Q32 Bio's debt to equity has soared by 84% from the previous quarter
QTTB's equity has dropped by 79% year-on-year and by 45% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.